SlideShare a Scribd company logo
1 of 46
GENE THERAPY




 P. K. Choudhury (Ph. D, 1st year,
              Dairy Microbiology)
Genes……......
• Are carried on a chromosome

• The basic unit of heredity

• Encode how to make a protein
               DNARNA proteins

• Proteins carry out most of life’s function.

• When altered causes dysfunction of a protein

• When there is a mutation in the gene, then it will change the
  codon, which will change which amino acid is called for which
  will change the conformation of the protein which will change
  the function of the protein. Genetic disorders result from
  mutations in the genome.
What is Gene Therapy
•   It is a technique for correcting defective genes that
    are responsible for disease development

•   There are four approaches:

    1.   A normal gene inserted to compensate for a nonfunctional
         gene.

    2.   An abnormal gene traded for a normal gene

    3.   An abnormal gene repaired through selective reverse
         mutation

    4.   Change the regulation of gene pairs
Background…………….
• 1970s Gene surgery proposal

• 1980s Great momentum to GT

• 1983 Gene therapy Lesch-Nyhan disease GT

• In 1988 (OTA)US Differentiate in somatic & germ LINE gene
  therapy

• September 14, 1990 ADA deficiency GT(W. French Anderson
  and colleagues)successful

• IN 1991 US govt.$58 million for gene therapy research

• Oct.1999.Jesse Jelsinger first fatality in human gene EXP
  :Multiple organ failure.(Ornithine Trancarbamylase
  Deficiency)

•2002 X-SCID: Fatal Leukemia
The First Case……….

• The first gene therapy was performed on
  September 14th, 1990

  • Ashanti DeSilva was treated for SCID
     • Sever combined immunodeficiency
  • Doctors removed her white blood cells,
    inserted the missing gene into the WBC, and
    then put them back into her blood stream.
  • This strengthened her immune system
  • Only worked for a few months 
How It Works………….
• A vector delivers the therapeutic gene into a
  patient’s target cell

• The target cells become infected with the viral vector

• The vector’s genetic material is inserted into the
  target cell

• Functional proteins are created from the therapeutic
  gene causing the cell to return to a normal state
Types: Gene Therapy


 Somatic gene therapy:
      a. Ex vivo gene therapy
      b. In vivo gene therapy



 Germline & embryonic gene therapy:
a. Human ex-vivo gene therapy
b. Human in-vivo gene thepary
Germline and embryonic gene therapy

1. Germline gene therapy refers to the permanent
   transfer of a gene into sperm or egg cells.

2. Embryonic gene therapy refers to the
   permanent transfer of a gene into the cells of
   an early embryo, just after the sperm and egg
   unite.

3. In both cases, the delivered gene would
   become a permanent part of cells in the
   resulting adult.
Transfection Technology

• Calcium phosphate     • Gold nanoparticles (1 to 3

• Electroporation        micrometer) :800psi

• Microinjection        • Chitosan

• Elevated temprature

• DEAE dextran

• Cationic liposome

• Activated dendrimer
Gene Transfer Vehicles
• Viral vector:
   -Retroviruses
   -Adenoviruses (dsDNA)
   -Adeno-associated viruses(ssDNA)
    -Herpes simplex virus(HSV)

• Non-viral methods:
      -Naked DNA
      -Anti sesne Oligonucleotides
      -Lipoplexes
      -Prodrug activation therapy
      -Ribozymes
      -Chimeroplasty
      -Schistosoma egg Proteins
Ideal gene delivery system……

 Biocompatible

 Non-immunogenic

 Stable in blood stream

 Protect DNA during transport

 Small enough to extravagate

 Cell and tissue specific
The Ideal Vector for Gene Transfer

• High concentration of virus allowing many cells to be infected or
  transduced

• Convenience and reproducibility of production

• Ability to transduce dividing and non-dividing cells
• Ability to integrate into a site-specific location in the host
  chromosome, or to be successfully maintained as stable episome
• A transcriptional unit that can respond to manipulation of its
  regulatory elements

• Ability to target the desired type of cell

• No components that elicit an immune response
Hallmarks of successful gene delivery

   1. Targeting the right cells

   2. Activating the gene

   3. Integrating the gene in the cells

   4. Avoiding harmful side effects
Retrovirus vector system
How one know whether a disorder is a
   good candidate for gene therapy ?

 Does the condition result from mutations in one or more genes?
 Which genes are involved?
 What one know about the biology of the disorder?
    Which tissues are affected
    What role does the protein encoded by the gene play within
     the cells of that tissue?
    Exactly how do mutations in the gene affect the protein's
     function?

 Will adding a normal copy of the gene fix the problem in the
  affected tissue?
 Can one deliver the gene to cells of the affected tissue?
Step 1: Learn about the disease

Is the disorder a good candidate for gene therapy?
 To find out, study the disease
    1) Get money for the project

    2) Get approval for the project

     3) Perform clinical research

     4) Perform biological research

     5) DECISION: Is the disorder a good candidate for gene
          therapy?
From Research to Trials……………..

•   Understand the biology behind the disorder

•   Develop the treatment approach

•   Test its effectiveness in biological models of the
    disease

•   Establish its safety in humans
Step 2: design a gene therapy

  1) Use your knowledge of the disorder to design a
    gene therapy
  2) Test the therapy in appropriate models of the
    disease
  3) DECISION: Does your therapy look promising?


Step 3: Get money and approval for clinical trials

  1) Get money for the trials
  2) Get approval for the trials
STEP 4: Phase One clinical trial
  1) Establish safety and dosage limits in a small group of people (20-
     80)

  2) DECISION: Does your therapy still look promising?


STEP 5: Phase Two clinical trial
  1)Test the efficacy and safety in a larger group of people (100-300)

  2) DECISION: Is your therapy effective in a larger group of people?


     • Use your knowledge of the disorder to design a gene therapy
     • Test the therapy in appropriate models of the disease
     • DECISION: Does your therapy look promising?
Step 6: Phase Three clinical trial
  1) Test the therapy in a large group of people (1,000-3,000)

  2) DECISION: Is your treatment successful?



Step 7: Get FDA&RAC(NIH) approval for general clinical
  use
  Write proposals, fill out paperwork, answer questions and wait for approval



Step 8: Phase Four clinical trial
  Further test the efficacy and optimal use of the treatment in general use
Cystic Fibrosis
 Defective gene (called delta F508) protein
  (cystic fibrosis transmembrane conductance
  regulator - CFTR)
 Flow of salt (sodium)

 salt is trapped
 overproducing bodily      secretions   such   as
  water, sweat and mucus
 secretions then build up in the body
Pedigree Analysis
Gene Therapy for Cystic Fibrosis
• Cystic fibrosis should be an ideal candidate for
  gene therapy, for four main reasons:

• (1) it is a single gene defect;
• (2) it is a recessive condition, with heterozygotes
  being phenotypically normal (suggesting gene
  dosage effects are not critical)
• (3) the main pathology is in the lung, which is
  accessible for treatment;
• (4) it is a progressive disease with a virtually normal
  phenotype at birth, offering a therapeutic window.
Gene Therapy :Cystic Fibrosis


1993 vector used: Adenovirus
CFTR (cystic fibrosis transmembrane regulator)
1995 liposome : cationic liposome-based systems
1998 Adeno-associated virus
Gene therapy in animals
• Hemophilia A: Clotting factor VIII has introduced in Rat and
  Dog                                           (Xu et al., 2005)

• Epilepsy: Type A receptors - In Rat
                                                  (Brooks et al., 2002 )

• Deafness: Atoh1 or Math1- Guinea pigs
                                                   (Izumikawa, 2003)

• Mastitis: lysostaphin gene in Jersey cattle
                                           (Robert-J-Wall et al., 2007)
• Blindness: GC1 gene in incubating egg
                                        (Semple Rowland et al., 2005)
Problems with Gene Therapy………
• Short Lived
   – Hard to rapidly integrate therapeutic DNA into genome and
     rapidly dividing nature of cells prevent gene therapy from long
     time
   – Would have to have multiple rounds of therapy

•   Immune Response
     – new things introduced leads to immune response
     – increased response when a repeat offender enters

• Viral Vectors
   – patient could have toxic, immune, inflammatory response
   – also may cause disease once inside

• Multigene Disorders
   – Heart disease, high blood pressure, Alzheimer’s, arthritis and
     diabetes are hard to treat because you need to introduce more
     than one gene
• May induce a tumor if integrated in a tumor suppressor gene
  because insertional mutagenesis
Social & Ethical issues
• Privacy & Confidentiality

• Psychological Impact& Stigmatization

• Available to rich & powerful

• Playing with God

• Designer babies
• Accumulation of defective genes in future generation
• Mutation or defective arrangement of genes

• Probability of occurrence of new diseases.
Recent Developments
• Genes get into brain using liposomes coated in polymer call
  polyethylene glycol
   – potential for treating Parkinson’s disease

• RNA interference or gene silencing to treat Huntington’s
   – siRNAs used to degrade RNA of particular sequence
   – abnormal protein wont be produced

• Create tiny liposomes that can carry therapeutic DNA through
  pores of nuclear membrane

•   Sickle cell successfully treated in mice
Conclusions………
• Neurogenic disease may be cured e.g. Alzeimer & Parkinson's
  Disease (life threatening diseases)

• Difference types of Cancer gene therapy trials may get
  success in future

• Germ cell gene therapy trials may get success in curing
  hereditary diseases

• Pharmacogenetics & Geneticular molecular biotechnology

• Applicable in livestock species.

• GT: cautiously & seriously evaluate
Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana   5th Dec, 2011
Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana   5th Dec, 2011
Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana   5th Dec, 2011

More Related Content

What's hot

Gene therapy and gene delivery systems
Gene therapy and gene delivery systemsGene therapy and gene delivery systems
Gene therapy and gene delivery systemsSalmanHashmi10
 
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemia
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemiaGene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemia
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemiaD.R. Chandravanshi
 
Gene therapy in clinical applications
Gene therapy in clinical applicationsGene therapy in clinical applications
Gene therapy in clinical applicationsDr. Ishan Y. Pandya
 
Gene therapy
Gene therapy Gene therapy
Gene therapy arushe143
 
Genetherapy
GenetherapyGenetherapy
GenetherapyboBa JOo
 
Gene therapy
Gene   therapyGene   therapy
Gene therapyPV. Viji
 
Gene Therapy, Applications and Recent advances
Gene Therapy, Applications and Recent advancesGene Therapy, Applications and Recent advances
Gene Therapy, Applications and Recent advancesUrvashi Shakarwal
 
Gene therapy- The hope beyond Myth
Gene therapy- The hope beyond MythGene therapy- The hope beyond Myth
Gene therapy- The hope beyond MythSuðesshnã Rãy
 

What's hot (20)

Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy and gene delivery systems
Gene therapy and gene delivery systemsGene therapy and gene delivery systems
Gene therapy and gene delivery systems
 
Gene therapy
Gene  therapyGene  therapy
Gene therapy
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemia
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemiaGene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemia
Gene therapy of genetic disorders like hepatitis, neuroblastoma, thalassemia
 
GENE THERAPY AND ITS APPLICATION
GENE THERAPY AND ITS APPLICATIONGENE THERAPY AND ITS APPLICATION
GENE THERAPY AND ITS APPLICATION
 
Gene therapy in clinical applications
Gene therapy in clinical applicationsGene therapy in clinical applications
Gene therapy in clinical applications
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy
Gene therapy Gene therapy
Gene therapy
 
Human gene therapy
Human gene therapyHuman gene therapy
Human gene therapy
 
Genetherapy
GenetherapyGenetherapy
Genetherapy
 
Gene therapy
Gene   therapyGene   therapy
Gene therapy
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene delivery system
Gene delivery systemGene delivery system
Gene delivery system
 
Gene Therapy, Applications and Recent advances
Gene Therapy, Applications and Recent advancesGene Therapy, Applications and Recent advances
Gene Therapy, Applications and Recent advances
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene transfer technologies
Gene transfer technologiesGene transfer technologies
Gene transfer technologies
 
Gene therapy- The hope beyond Myth
Gene therapy- The hope beyond MythGene therapy- The hope beyond Myth
Gene therapy- The hope beyond Myth
 

Similar to Gene therapy

Gene therapy shi.,
Gene therapy shi.,Gene therapy shi.,
Gene therapy shi.,shoaa311
 
Gene rx [autosaved]
Gene rx [autosaved]Gene rx [autosaved]
Gene rx [autosaved]chandiniyrao
 
shoaibgeneticvariatin-180115093327.pptx
shoaibgeneticvariatin-180115093327.pptxshoaibgeneticvariatin-180115093327.pptx
shoaibgeneticvariatin-180115093327.pptxalizain9604
 
terapi gen kelainan genetik genetic disorders treatment
terapi gen kelainan genetik genetic disorders treatmentterapi gen kelainan genetik genetic disorders treatment
terapi gen kelainan genetik genetic disorders treatmentHendrik Sutopo
 
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzj
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzjGene therapy.pptxjjjjnnnsnskskslsllssnnznzj
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzjanshikabhatnagar1299
 
DNA recombinant technology on insulin modification
DNA recombinant technology on insulin modificationDNA recombinant technology on insulin modification
DNA recombinant technology on insulin modificationaulia624292
 
BTG 708 GENE THERAPY.pptx
BTG 708 GENE THERAPY.pptxBTG 708 GENE THERAPY.pptx
BTG 708 GENE THERAPY.pptxRUTH AFUNWA
 
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptx
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptxNUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptx
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptxPRAMESHPANWAR1
 

Similar to Gene therapy (20)

Gene therapy shi.,
Gene therapy shi.,Gene therapy shi.,
Gene therapy shi.,
 
Gene thepapy.pptx
Gene thepapy.pptxGene thepapy.pptx
Gene thepapy.pptx
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene Therapy
Gene TherapyGene Therapy
Gene Therapy
 
Gene rx [autosaved]
Gene rx [autosaved]Gene rx [autosaved]
Gene rx [autosaved]
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
genetic variation
 genetic variation genetic variation
genetic variation
 
Gene therapy
Gene therapy  Gene therapy
Gene therapy
 
shoaibgeneticvariatin-180115093327.pptx
shoaibgeneticvariatin-180115093327.pptxshoaibgeneticvariatin-180115093327.pptx
shoaibgeneticvariatin-180115093327.pptx
 
terapi gen kelainan genetik genetic disorders treatment
terapi gen kelainan genetik genetic disorders treatmentterapi gen kelainan genetik genetic disorders treatment
terapi gen kelainan genetik genetic disorders treatment
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzj
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzjGene therapy.pptxjjjjnnnsnskskslsllssnnznzj
Gene therapy.pptxjjjjnnnsnskskslsllssnnznzj
 
DNA recombinant technology on insulin modification
DNA recombinant technology on insulin modificationDNA recombinant technology on insulin modification
DNA recombinant technology on insulin modification
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Gene therapy
Gene therapy Gene therapy
Gene therapy
 
BTG 708 GENE THERAPY.pptx
BTG 708 GENE THERAPY.pptxBTG 708 GENE THERAPY.pptx
BTG 708 GENE THERAPY.pptx
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptx
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptxNUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptx
NUCLEIC ACID BASED THERAPEUTIC DELIVERY SYSTEM by pramesh..pptx
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 

Recently uploaded

Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991RKavithamani
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...RKavithamani
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 

Recently uploaded (20)

Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
Industrial Policy - 1948, 1956, 1973, 1977, 1980, 1991
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...
Privatization and Disinvestment - Meaning, Objectives, Advantages and Disadva...
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 

Gene therapy

  • 1. GENE THERAPY P. K. Choudhury (Ph. D, 1st year, Dairy Microbiology)
  • 2. Genes……...... • Are carried on a chromosome • The basic unit of heredity • Encode how to make a protein DNARNA proteins • Proteins carry out most of life’s function. • When altered causes dysfunction of a protein • When there is a mutation in the gene, then it will change the codon, which will change which amino acid is called for which will change the conformation of the protein which will change the function of the protein. Genetic disorders result from mutations in the genome.
  • 3. What is Gene Therapy • It is a technique for correcting defective genes that are responsible for disease development • There are four approaches: 1. A normal gene inserted to compensate for a nonfunctional gene. 2. An abnormal gene traded for a normal gene 3. An abnormal gene repaired through selective reverse mutation 4. Change the regulation of gene pairs
  • 4. Background……………. • 1970s Gene surgery proposal • 1980s Great momentum to GT • 1983 Gene therapy Lesch-Nyhan disease GT • In 1988 (OTA)US Differentiate in somatic & germ LINE gene therapy • September 14, 1990 ADA deficiency GT(W. French Anderson and colleagues)successful • IN 1991 US govt.$58 million for gene therapy research • Oct.1999.Jesse Jelsinger first fatality in human gene EXP :Multiple organ failure.(Ornithine Trancarbamylase Deficiency) •2002 X-SCID: Fatal Leukemia
  • 5. The First Case………. • The first gene therapy was performed on September 14th, 1990 • Ashanti DeSilva was treated for SCID • Sever combined immunodeficiency • Doctors removed her white blood cells, inserted the missing gene into the WBC, and then put them back into her blood stream. • This strengthened her immune system • Only worked for a few months 
  • 6. How It Works…………. • A vector delivers the therapeutic gene into a patient’s target cell • The target cells become infected with the viral vector • The vector’s genetic material is inserted into the target cell • Functional proteins are created from the therapeutic gene causing the cell to return to a normal state
  • 7. Types: Gene Therapy  Somatic gene therapy: a. Ex vivo gene therapy b. In vivo gene therapy  Germline & embryonic gene therapy:
  • 8. a. Human ex-vivo gene therapy
  • 9. b. Human in-vivo gene thepary
  • 10.
  • 11. Germline and embryonic gene therapy 1. Germline gene therapy refers to the permanent transfer of a gene into sperm or egg cells. 2. Embryonic gene therapy refers to the permanent transfer of a gene into the cells of an early embryo, just after the sperm and egg unite. 3. In both cases, the delivered gene would become a permanent part of cells in the resulting adult.
  • 12. Transfection Technology • Calcium phosphate • Gold nanoparticles (1 to 3 • Electroporation micrometer) :800psi • Microinjection • Chitosan • Elevated temprature • DEAE dextran • Cationic liposome • Activated dendrimer
  • 13. Gene Transfer Vehicles • Viral vector: -Retroviruses -Adenoviruses (dsDNA) -Adeno-associated viruses(ssDNA) -Herpes simplex virus(HSV) • Non-viral methods: -Naked DNA -Anti sesne Oligonucleotides -Lipoplexes -Prodrug activation therapy -Ribozymes -Chimeroplasty -Schistosoma egg Proteins
  • 14.
  • 15.
  • 16. Ideal gene delivery system……  Biocompatible  Non-immunogenic  Stable in blood stream  Protect DNA during transport  Small enough to extravagate  Cell and tissue specific
  • 17. The Ideal Vector for Gene Transfer • High concentration of virus allowing many cells to be infected or transduced • Convenience and reproducibility of production • Ability to transduce dividing and non-dividing cells • Ability to integrate into a site-specific location in the host chromosome, or to be successfully maintained as stable episome • A transcriptional unit that can respond to manipulation of its regulatory elements • Ability to target the desired type of cell • No components that elicit an immune response
  • 18. Hallmarks of successful gene delivery 1. Targeting the right cells 2. Activating the gene 3. Integrating the gene in the cells 4. Avoiding harmful side effects
  • 20.
  • 21.
  • 22. How one know whether a disorder is a good candidate for gene therapy ?  Does the condition result from mutations in one or more genes?  Which genes are involved?  What one know about the biology of the disorder?  Which tissues are affected  What role does the protein encoded by the gene play within the cells of that tissue?  Exactly how do mutations in the gene affect the protein's function?  Will adding a normal copy of the gene fix the problem in the affected tissue?  Can one deliver the gene to cells of the affected tissue?
  • 23. Step 1: Learn about the disease Is the disorder a good candidate for gene therapy? To find out, study the disease 1) Get money for the project 2) Get approval for the project 3) Perform clinical research 4) Perform biological research 5) DECISION: Is the disorder a good candidate for gene therapy?
  • 24. From Research to Trials…………….. • Understand the biology behind the disorder • Develop the treatment approach • Test its effectiveness in biological models of the disease • Establish its safety in humans
  • 25. Step 2: design a gene therapy 1) Use your knowledge of the disorder to design a gene therapy 2) Test the therapy in appropriate models of the disease 3) DECISION: Does your therapy look promising? Step 3: Get money and approval for clinical trials 1) Get money for the trials 2) Get approval for the trials
  • 26. STEP 4: Phase One clinical trial 1) Establish safety and dosage limits in a small group of people (20- 80) 2) DECISION: Does your therapy still look promising? STEP 5: Phase Two clinical trial 1)Test the efficacy and safety in a larger group of people (100-300) 2) DECISION: Is your therapy effective in a larger group of people? • Use your knowledge of the disorder to design a gene therapy • Test the therapy in appropriate models of the disease • DECISION: Does your therapy look promising?
  • 27. Step 6: Phase Three clinical trial 1) Test the therapy in a large group of people (1,000-3,000) 2) DECISION: Is your treatment successful? Step 7: Get FDA&RAC(NIH) approval for general clinical use Write proposals, fill out paperwork, answer questions and wait for approval Step 8: Phase Four clinical trial Further test the efficacy and optimal use of the treatment in general use
  • 28.
  • 29.
  • 30.
  • 31. Cystic Fibrosis  Defective gene (called delta F508) protein (cystic fibrosis transmembrane conductance regulator - CFTR)  Flow of salt (sodium)  salt is trapped  overproducing bodily secretions such as water, sweat and mucus  secretions then build up in the body
  • 32.
  • 33.
  • 34.
  • 36. Gene Therapy for Cystic Fibrosis • Cystic fibrosis should be an ideal candidate for gene therapy, for four main reasons: • (1) it is a single gene defect; • (2) it is a recessive condition, with heterozygotes being phenotypically normal (suggesting gene dosage effects are not critical) • (3) the main pathology is in the lung, which is accessible for treatment; • (4) it is a progressive disease with a virtually normal phenotype at birth, offering a therapeutic window.
  • 37. Gene Therapy :Cystic Fibrosis 1993 vector used: Adenovirus CFTR (cystic fibrosis transmembrane regulator) 1995 liposome : cationic liposome-based systems 1998 Adeno-associated virus
  • 38.
  • 39. Gene therapy in animals • Hemophilia A: Clotting factor VIII has introduced in Rat and Dog (Xu et al., 2005) • Epilepsy: Type A receptors - In Rat (Brooks et al., 2002 ) • Deafness: Atoh1 or Math1- Guinea pigs (Izumikawa, 2003) • Mastitis: lysostaphin gene in Jersey cattle (Robert-J-Wall et al., 2007) • Blindness: GC1 gene in incubating egg (Semple Rowland et al., 2005)
  • 40. Problems with Gene Therapy……… • Short Lived – Hard to rapidly integrate therapeutic DNA into genome and rapidly dividing nature of cells prevent gene therapy from long time – Would have to have multiple rounds of therapy • Immune Response – new things introduced leads to immune response – increased response when a repeat offender enters • Viral Vectors – patient could have toxic, immune, inflammatory response – also may cause disease once inside • Multigene Disorders – Heart disease, high blood pressure, Alzheimer’s, arthritis and diabetes are hard to treat because you need to introduce more than one gene • May induce a tumor if integrated in a tumor suppressor gene because insertional mutagenesis
  • 41. Social & Ethical issues • Privacy & Confidentiality • Psychological Impact& Stigmatization • Available to rich & powerful • Playing with God • Designer babies • Accumulation of defective genes in future generation • Mutation or defective arrangement of genes • Probability of occurrence of new diseases.
  • 42. Recent Developments • Genes get into brain using liposomes coated in polymer call polyethylene glycol – potential for treating Parkinson’s disease • RNA interference or gene silencing to treat Huntington’s – siRNAs used to degrade RNA of particular sequence – abnormal protein wont be produced • Create tiny liposomes that can carry therapeutic DNA through pores of nuclear membrane • Sickle cell successfully treated in mice
  • 43. Conclusions……… • Neurogenic disease may be cured e.g. Alzeimer & Parkinson's Disease (life threatening diseases) • Difference types of Cancer gene therapy trials may get success in future • Germ cell gene therapy trials may get success in curing hereditary diseases • Pharmacogenetics & Geneticular molecular biotechnology • Applicable in livestock species. • GT: cautiously & seriously evaluate
  • 44. Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana 5th Dec, 2011
  • 45. Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana 5th Dec, 2011
  • 46. Gene Therapy and Genetic Engineering, P. K. Choudhury, NDRI, Karnal, Haryana 5th Dec, 2011